Real-world study of the treatments following trastuzumab-emtansine for HER2-positive metastatic breast cancer: A multicentral cohort study (WJOG12519B).

Sasagu Kurozumi,Takamichi Yokoe,Kazuki Nozawa,Yukinori Ozaki,Tetsuyo Maeda,Shu Yazaki,Mai Onishi,Akihiro Fujimoto,Sayuka Nakayama,Yuko Tsuboguchi,Tsutomu Iwasa,Hitomi Sakai,Misato Ogata,Mitsuo Terada,Meiko Nishimura,Takuma Onoe,Jun Masuda,Michiko Kurikawa,Mototsugu Shimokawa,Toshimi Takano

Real-world study of the treatments following trastuzumab-emtansine for HER2-positive metastatic breast cancer: A multicentral cohort study (WJOG12519B).

2020

e13019Background: Since trastuzumab emtansine (T-DM1) was established as a standard treatment option, the treatment strategy of metastatic HER2-positive breast cancer has markedly changed. However,...

Keywords:

Oncology
Metastatic breast cancer
Internal medicine
Trastuzumab emtansine
Pathology
Cohort study
Medicine
Breast cancer
Standard treatment
treatment strategy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations